大湄公河次区域中医药国际合作现状与发展对策研究
|
摘要
GMS是中医药国际合作与产品出口的重要地区,也是我国"一带一路"倡议实施的重点地区。近年来,中国与GMS其他成员国的中医药合作呈现两极分化,两大经济体泰国与越南形成较大中医药出口市场,合作日益密切;缅甸、老挝与柬埔寨出口市场小,合作仍处于初期阶段。GMS中医药国际合作主要模式为政府合作、资源共享、服务贸易与人才交流,存在的主要问题为中医药标准体系还未接轨与知识保护面临挑战、文化差异与地缘政治竞争以及服务产业体系和管理体系不完善。依托"大湄公河次区域"与"一带一路"倡议融入经贸建设、进一步构建中医药国际标准体系、加强中医药文化传播以及合作办学与企业进驻成为促进GMS合作不断深化的有效对策。
The Greater Mekong Sub-region(GMS) is an important area for international cooperation on and export of Chinese medicine and also a key area for the implementation of China' s "One Belt, One Road" initiative. In recent years, China's cooperation with other countries in GMS has been polarized. The two major economies, Thailand and Vietnam, have become large export markets for Chinese medicine, and their cooperation with China is getting increasingly close. However, the export markets of Myanmar, Laos and Cambodia are small, and the cooperation is still in its infancy. Among the main cooperation modes of Chinese medicine in GMS are inter-governmental cooperation, resource sharing, service trade and talent exchange. There are still rigorous challenges in the Chinese medicine standard system improvement, knowledge protection, cultural differences and geopolitical competition, and service industry system and management system. In view of the current situation and to promote the deepening of GMS cooperation, we propose the following countermeasures: relying on the "Greater Mekong Sub-region" and the "Belt and Road" strategies to integrate into the economic and trade construction; further constructing the international standard system of Chinese medicine; strengthening the spread of Chinese medicine culture; and carrying out cooperation in running schools and attracting enterprises.
The Greater Mekong Sub-region(GMS) is an important area for international cooperation on and export of Chinese medicine and also a key area for the implementation of China' s "One Belt, One Road" initiative. In recent years, China's cooperation with other countries in GMS has been polarized. The two major economies, Thailand and Vietnam, have become large export markets for Chinese medicine, and their cooperation with China is getting increasingly close. However, the export markets of Myanmar, Laos and Cambodia are small, and the cooperation is still in its infancy. Among the main cooperation modes of Chinese medicine in GMS are inter-governmental cooperation, resource sharing, service trade and talent exchange. There are still rigorous challenges in the Chinese medicine standard system improvement, knowledge protection, cultural differences and geopolitical competition, and service industry system and management system. In view of the current situation and to promote the deepening of GMS cooperation, we propose the following countermeasures: relying on the "Greater Mekong Sub-region" and the "Belt and Road" strategies to integrate into the economic and trade construction; further constructing the international standard system of Chinese medicine; strengthening the spread of Chinese medicine culture; and carrying out cooperation in running schools and attracting enterprises.
引文
[1]熊水明,邢永革.中医药在泰国的传播和发展现状分析[J].环球中医药,2019,12(3).
[2]郭宇航,方显明,蒋基昌,陈靖红,陈真珍,杨宁华.泰国中医药发展历史现状调查及思考[J].东南亚纵横,2009,(3).
[3]马云丽.中国—东盟背景下提升我国中药在越南市场竞争力的对策研究[J].广西经济管理干部学院学报,2017,29(2).
[4]张春梅,王兰,周微,彭腾,舒光明.越南传统药品管理及注册政策的分析[J].现代药物与临床,2012,27(3).
[5]赵少钦,周青,孙永林,吴非,左媛媛.越南传统医学发展现状及对策研究[J].亚太传统医药,2017,13(11).
[6]马云丽.中国—东盟背景下提升我国中药在越南市场竞争力的对策研究[J].广西经济管理干部学院学报,2017,29(2).
[7]苏芮,庄庭怡,苏庆民,图雅.东南亚“一带一路”沿线国家中医药政策及市场调查[J].环球中医药,2018,11(9).
[8]林文勋,郑永年.澜湄合作新机遇与中国—东盟关系新篇章——第七届西南论坛暨澜湄合作智库论坛论文集[C].北京:社会科学文献出版社,2012.
[9]孙东东,袁盼,钱洁,申俊龙.“一带一路”倡议下中医药国际合作的健康资源共享途径探讨[J].中医杂志,2019,60(3).
[10]聂平香.我国中医药服务贸易发展路径选择及对策[J].国际贸易,2016,(5).
[11]施雪斐,张建忠,宋欣阳,金阿宁.中东欧16国中医药发展脉络与策略研究[J].中华中医药杂志,2019,34(3).
[12]本刊通讯员.我国传统医药知识保护遭遇多重挑战[J].中国中医药信息杂志,2013,20(4).
[13]张如霞,汤少梁.“一带一路”进程中中医药国际合作机制研究[J].中草药,2018,49(7).
[14]张宗明,申宁.加强中医文化教育,提高大学生思想道德素质[J].医学与社会,2010,23(8).
[15]宋效峰.湄公河次区域的地缘政治与公共产品供给[J].江南社会学院学报,2014,16(4).
[16]李玫姬.“一带一路”战略背景下中医药文化国际传播的机遇、挑战与对策[J].学术论坛,2016,39(4).
[17]文少彪,朱杰进.中国参与中东地区卫生治理的多视角分析[J].阿拉伯世界研究,2016,(4).
[18]中医药健康服务发展规划(2015—2020)[EB/OL].http://www.gov.cn/zhengce/content_9704.htm.
[19]国家卫生计生委关于推进“一带一路”卫生交流合作三年实施方案( 2015—2017) [EB/OL].http://www.nhfpc.gov.cn/ewebeditor/uploadfile/2015/10/20151023161915772.docx.
[20]周延松.中医孔子学院的语言文化传播及其模式构建[J].世界中西医结合杂志,2014,9(11).
[2]郭宇航,方显明,蒋基昌,陈靖红,陈真珍,杨宁华.泰国中医药发展历史现状调查及思考[J].东南亚纵横,2009,(3).
[3]马云丽.中国—东盟背景下提升我国中药在越南市场竞争力的对策研究[J].广西经济管理干部学院学报,2017,29(2).
[4]张春梅,王兰,周微,彭腾,舒光明.越南传统药品管理及注册政策的分析[J].现代药物与临床,2012,27(3).
[5]赵少钦,周青,孙永林,吴非,左媛媛.越南传统医学发展现状及对策研究[J].亚太传统医药,2017,13(11).
[6]马云丽.中国—东盟背景下提升我国中药在越南市场竞争力的对策研究[J].广西经济管理干部学院学报,2017,29(2).
[7]苏芮,庄庭怡,苏庆民,图雅.东南亚“一带一路”沿线国家中医药政策及市场调查[J].环球中医药,2018,11(9).
[8]林文勋,郑永年.澜湄合作新机遇与中国—东盟关系新篇章——第七届西南论坛暨澜湄合作智库论坛论文集[C].北京:社会科学文献出版社,2012.
[9]孙东东,袁盼,钱洁,申俊龙.“一带一路”倡议下中医药国际合作的健康资源共享途径探讨[J].中医杂志,2019,60(3).
[10]聂平香.我国中医药服务贸易发展路径选择及对策[J].国际贸易,2016,(5).
[11]施雪斐,张建忠,宋欣阳,金阿宁.中东欧16国中医药发展脉络与策略研究[J].中华中医药杂志,2019,34(3).
[12]本刊通讯员.我国传统医药知识保护遭遇多重挑战[J].中国中医药信息杂志,2013,20(4).
[13]张如霞,汤少梁.“一带一路”进程中中医药国际合作机制研究[J].中草药,2018,49(7).
[14]张宗明,申宁.加强中医文化教育,提高大学生思想道德素质[J].医学与社会,2010,23(8).
[15]宋效峰.湄公河次区域的地缘政治与公共产品供给[J].江南社会学院学报,2014,16(4).
[16]李玫姬.“一带一路”战略背景下中医药文化国际传播的机遇、挑战与对策[J].学术论坛,2016,39(4).
[17]文少彪,朱杰进.中国参与中东地区卫生治理的多视角分析[J].阿拉伯世界研究,2016,(4).
[18]中医药健康服务发展规划(2015—2020)[EB/OL].http://www.gov.cn/zhengce/content_9704.htm.
[19]国家卫生计生委关于推进“一带一路”卫生交流合作三年实施方案( 2015—2017) [EB/OL].http://www.nhfpc.gov.cn/ewebeditor/uploadfile/2015/10/20151023161915772.docx.
[20]周延松.中医孔子学院的语言文化传播及其模式构建[J].世界中西医结合杂志,2014,9(11).
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |